Dr Ankur Mutreja is an experienced global health scientist who has worked in both academia and biotech industry for over a decade. With extensive knowledge in the area of outbreak surveillance, vaccines, diagnostics and regulation, he is currently working full time as a Group Leader in Global Health (Infectious Diseases) at the Department of Medicine, University of Cambridge.
In parallel, as an Honorary Faculty in several institutes of repute globally, he leads several public health projects connecting Global South with Global North. Dr Mutreja’s work is guiding WHO’s cholera eradication campaign and his reverse vaccinology expertise has helped in the design of broadly protective ETEC vaccine (at MSD-Wellcome Hilleman Labs) and a globally representative Group A Streptococcus vaccine targeting Pharyngitis and Rheumatic Heart Disease (at Novartis Vaccines). More recently his work on diphtheria has led to a fresh discussion on reformulation of decades old diphtheria vaccine.
With prestigious grants with funding from DBT, Wellcome, MRC, ESRC, NIHR-BRC, Alborada Trust, Hamied Foundation and an excellent publication record, Dr Mutreja also sits on the scientific and management committees of Govt panels, public health agencies, biotech companies and vaccine networks.